Atea Pharmaceuticals, Inc. — Director's Dealing 2024

Jun 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2024-06-20

Reporting Person: Polsky Bruce (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-20	Common Stock	S	17544	$3.4852	Disposed	65606	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-21	Restricted Stock Units	$	A	29600	Acquired		Common Stock (29600)	Direct
2024-06-21	Stock Option (Right to Buy)	$3.44	A	41200	Acquired	2034-06-20	Common Stock (41200)	Direct

Footnotes

F1: The shares were sold solely to cover taxes upon the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.53, inclusive.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.